BioCentury | Aug 28, 2020
Distillery Therapeutics

Preventing thrombosis using nanoparticles loaded with anti-G protein peptides

DISEASE CATEGORY: Cardiovascular INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury. The...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BioCentury | Mar 1, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...
BioCentury | Feb 25, 2019
Clinical News

Brilinta reduces CV events in patients without prior heart attack, stroke

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...
BioCentury | Feb 1, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
BioCentury | Jan 28, 2019
Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
BioCentury | Dec 21, 2018
Clinical News

Idorsia's P2RY12 antagonist inhibits platelet aggregation within 15 minutes

Idorsia Ltd. (SIX:IDIA) said single subcutaneous injections of selatogrel (ACT-246475) inhibited platelet aggregation within 15 minutes with its maximum effect extending over 4-8 hours depending on the dose in a pair of Phase II trials...
BioCentury | Nov 9, 2018
Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
BioCentury | Nov 8, 2018
Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
BioCentury | Oct 5, 2018
Clinical News

PhaseBio's PB2452 reverses antiplatelet activity of Brilinta in Phase I

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) said PB2452 (formerly MEDI2452) rapidly and completely reversed the antiplatelet activity of cardiovascular drug Brilinta ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) in a Phase I trial. The company is developing...
Items per page:
1 - 10 of 111